BRIEF-CSL And Lilly Enter Licensing Agreement For Clazakizumab

Reuters
Yesterday
BRIEF-CSL And Lilly Enter Licensing Agreement For Clazakizumab

Feb 18 (Reuters) - CSL Ltd CSL.AX:

  • CSL AND LILLY ENTER LICENSING AGREEMENT FOR CLAZAKIZUMAB

  • EXCLUSIVE LICENSING AGREEMENT GRANTING CERTAIN RIGHTS TO DEVELOP AND COMMERCIALISE CLAZAKIZUMAB

  • CSL WILL RECEIVE AN UPFRONT PAYMENT OF $100 MILLION

  • CSL WILL RETAIN EXCLUSIVE RIGHTS TO DEVELOP AND COMMERCIALISE CLAZAKIZUMAB FOR PREVENTION OF CARDIOVASCULAR EVENTS IN PATIENTS WITH END-STAGE KIDNEY DISEASE

Further company coverage: CSL.AX

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10